Inozyme Pharma Stock Revenue
| INZY Stock | USD 2.72 0.07 2.64% |
Inozyme Pharma fundamentals help investors to digest information that contributes to Inozyme Pharma's financial success or failures. It also enables traders to predict the movement of Inozyme Stock. The fundamental analysis module provides a way to measure Inozyme Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Inozyme Pharma stock.
| Last Reported | Projected for Next Year |
Inozyme | Revenue |
Inozyme Pharma Company Revenue Analysis
Inozyme Pharma's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Historical and Projected quarterly revenue of Inozyme
Projected quarterly revenue analysis of Inozyme Pharma provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Inozyme Pharma match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Inozyme Pharma's stock price.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Inozyme Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Inozyme Pharma reported 0.0 of revenue. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The revenue for all United States stocks is 100.0% higher than that of the company.
Inozyme Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Inozyme Pharma's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Inozyme Pharma could also be used in its relative valuation, which is a method of valuing Inozyme Pharma by comparing valuation metrics of similar companies.Inozyme Pharma is currently under evaluation in revenue category among its peers.
Inozyme Pharma Current Valuation Drivers
We derive many important indicators used in calculating different scores of Inozyme Pharma from analyzing Inozyme Pharma's financial statements. These drivers represent accounts that assess Inozyme Pharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Inozyme Pharma's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 265.9M | 482.7M | 160.7M | 39.7M | 220.8M | 263.1M | |
| Enterprise Value | 234.3M | 324.1M | 140.7M | 13.5M | 232.8M | 215.4M |
Inozyme Pharma ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Inozyme Pharma's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Inozyme Pharma's managers, analysts, and investors.Environmental | Governance | Social |
Inozyme Pharma Institutional Holders
Institutional Holdings refers to the ownership stake in Inozyme Pharma that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Inozyme Pharma's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Inozyme Pharma's value.| Shares | Millennium Management Llc | 2024-06-30 | 1.8 M | Samsara Biocapital, Llc | 2024-09-30 | 1.6 M | Saturn V Capital Management Llc | 2024-09-30 | 1.4 M | Sphera Funds Management Ltd. | 2024-09-30 | 1.2 M | Geode Capital Management, Llc | 2024-09-30 | 1.2 M | Blue Owl Capital Holdings Lp | 2024-09-30 | 1.1 M | Woodline Partners Lp | 2024-06-30 | 1 M | State Street Corp | 2024-06-30 | 1 M | Dimensional Fund Advisors, Inc. | 2024-09-30 | 446.2 K | Adage Capital Partners Gp Llc | 2024-06-30 | 5.7 M | Pivotal Bioventure Partners Investment Advisor Llc | 2024-06-30 | 4.5 M |
Inozyme Fundamentals
| Return On Equity | -0.79 | ||||
| Return On Asset | -0.36 | ||||
| Current Valuation | 85.42 M | ||||
| Shares Outstanding | 64.24 M | ||||
| Shares Owned By Insiders | 0.50 % | ||||
| Shares Owned By Institutions | 96.67 % | ||||
| Number Of Shares Shorted | 3.31 M | ||||
| Price To Book | 2.06 X | ||||
| EBITDA | (74.81 M) | ||||
| Net Income | (71.17 M) | ||||
| Cash And Equivalents | 151.48 M | ||||
| Cash Per Share | 3.77 X | ||||
| Total Debt | 46.59 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 14.54 X | ||||
| Book Value Per Share | 1.29 X | ||||
| Cash Flow From Operations | (70.67 M) | ||||
| Short Ratio | 10.99 X | ||||
| Earnings Per Share | (1.59) X | ||||
| Price To Earnings To Growth | (0.06) X | ||||
| Target Price | 18.75 | ||||
| Number Of Employees | 59 | ||||
| Beta | 1.54 | ||||
| Market Capitalization | 174.73 M | ||||
| Total Asset | 200.85 M | ||||
| Retained Earnings | (285.93 M) | ||||
| Working Capital | 181.56 M | ||||
| Net Asset | 200.85 M |
About Inozyme Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Inozyme Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Inozyme Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Inozyme Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Inozyme Stock Analysis
When running Inozyme Pharma's price analysis, check to measure Inozyme Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inozyme Pharma is operating at the current time. Most of Inozyme Pharma's value examination focuses on studying past and present price action to predict the probability of Inozyme Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inozyme Pharma's price. Additionally, you may evaluate how the addition of Inozyme Pharma to your portfolios can decrease your overall portfolio volatility.